Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3378
Source ID: NCT00326326
Associated Drug: Cp-778,875
Title: Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Dyslipidemia
Interventions: DRUG: CP-778,875
Outcome Measures: Primary: HDL-C Safety and Efficacy |
Sponsor/Collaborators: Sponsor: Pfizer
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 84
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
Start Date: 2006-07
Completion Date: 2007-06
Results First Posted:
Last Update Posted: 2009-05-07
Locations: Pfizer Investigational Site, Anniston, Alabama, 36207, United States|Pfizer Investigational Site, Huntsville, Alabama, 35801, United States|Pfizer Investigational Site, Greenbrae, California, 94904, United States|Pfizer Investigational Site, Los Angeles, California, 90057, United States|Pfizer Investigational Site, Walnut Creek, California, 94598, United States|Pfizer Investigational Site, DeFuniak Springs, Florida, 32435, United States|Pfizer Investigational Site, Destin, Florida, 32541, United States|Pfizer Investigational Site, Jupiter, Florida, 33458, United States|Pfizer Investigational Site, Melbourne, Florida, 32901, United States|Pfizer Investigational Site, Atlanta, Georgia, 30342, United States|Pfizer Investigational Site, Conyers, Georgia, 30094, United States|Pfizer Investigational Site, Chicago, Illinois, 60612, United States|Pfizer Investigational Site, Iowa City, Iowa, 52242, United States|Pfizer Investigational Site, Lexington, Kentucky, 40504, United States|Pfizer Investigational Site, Baltimore, Maryland, 21201, United States|Pfizer Investigational Site, Springfield, Missouri, 65807, United States|Pfizer Investigational Site, Omaha, Nebraska, 68131, United States|Pfizer Investigational Site, Las Vegas, Nevada, 89106, United States|Pfizer Investigational Site, Mount Vernon, New York, 10550, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, 73103, United States|Pfizer Investigational Site, Tulsa, Oklahoma, 74136, United States|Pfizer Investigational Site, Kingsport, Tennessee, 37660, United States|Pfizer Investigational Site, Bryan, Texas, 77802, United States|Pfizer Investigational Site, Houston, Texas, 77030, United States|Pfizer Investigational Site, San Antonio, Texas, 78229, United States|Pfizer Investigational Site, Newport News, Virginia, 23606, United States|Pfizer Investigational Site, Richmond, Virginia, 23225, United States|Pfizer Investigational Site, Richmond, Virginia, 23249, United States|Pfizer Investigational Site, Richmond, Virginia, 23294, United States|Pfizer Investigational Site, Yakima, Washington, 98902, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, 53209, United States
URL: https://clinicaltrials.gov/show/NCT00326326

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress